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Developing Mn-doped lead sulfide quantum dots
for MRI labels†
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Magnetic interactions of Mn2+ ions in lead sulfide (PbS) nanocrystals
with protons in water are probed by NMR and MRI. A thin layer of
capping molecules enables free solvent diﬀusion to the nanocrystal
surface resulting in a decrease of proton relaxation times. Magnetic
resonance imaging of neuronal cell pellets exposed to (PbMn)S at
non-toxic concentrations demonstrates their prospects as MRI-labels.
Doping of colloidal semiconductor nanocrystals (Quantum Dots,
QDs) with impurities has the potential to advance the use of QDs in
a range of applications from optoelectronic devices to biomedical
imaging.1,2 The optical stability and tuneability of the QD emission
oﬀer significant advantages for bioimaging and self-reporting drug
delivery systems, particularly in the near-infrared (NIR) wavelength
range 1000–1300 nm, where absorption of biological tissues and
light scattering are favourable for signal penetration through deep
tissues.2,3 On the other hand, doping with magnetic impurities4
in combination with the tuneable QD absorption could enable
development of multifunctional labels for combined Magnetic
Resonance Imaging (MRI) and fluorescence imaging.5 The
complementarity of these imaging techniques, i.e. high spatial
and temporal resolution of optical imaging and the non-invasive
anatomical three dimensional (3D) imaging capability of MRI, could
enable significant progress in medical diagnostics, for example,
during surgical procedures, which require real-time image guidance
and high resolution imaging.6
The advantages of colloidal semiconductor quantum dots for
fluorescence imaging have been widely explored7,8 and particular
interest has been recently focused on QDs with emission in
the near-infrared wavelength range.9 On the other hand, the
development of nanoparticles as MRI contrast agents has
mainly directed to iron oxide particles,5,10 Mn-clusters11,12
and bi-metallic nanoparticles.13,14 However, these do not fluoresce.
To achieve multifunctionality, diﬀerent hybrid systems have been
explored, including composite particles of QDs and iron oxides,5
and QDs with conjugated Gd(III)-chelates.15,16 These approaches
significantly increase the size of the probes and thus the use of
these nanostructures in medical imaging may be limited by
ineﬃcient transport through tissues and their clearance.17,18
Doping of colloidal QDs with transition metals (Mn, Fe, etc.)
could oﬀer an alternative strategy with minimal changes in
size or morphology, as demonstrated for visible II–VI19,20 and
I–III–VI21,22 QDs. In particular, Mn has been recently identified
as a promising alternative to Gd in MRI.23 Mn-Based nano-
particles can have a relaxivity comparable to that of Gd(III)
currently used in MRI as a contrast agent,24 but significantly
lower intrinsic cytotoxicity.20 Although chelated Mn-complexes
can also be employed in MRI, a Mn-doped QD would be less
susceptible to chemical reactions and could be designed to
combine within one structure magnetic properties with stable
and tuneable absorption and emission, thus providing a promising
route to multi-modal imaging. Furthermore, the nanoscale design
of magnetic interactions within a QD has the potential to advance
the use of nanoparticles in MRI and to open up new research
directions in medical imaging.
Here we examine magnetic interactions in Mn-doped lead
sulphide (PbS) semiconducting QDs capped with thioglycerols
(TGL) and demonstrate that these NIR fluorescent QDs can be
used as MRI labels (Fig. 1a and b). The capping molecules
provide the nanocrystal with a thin shell, which enables the
dispersion and solubilisation of the QDs in physiological
solvents and allows free diﬀusion of the water molecules in
close proximity to the QD surface, thus resulting in Mn-induced
change of the magnetic resonance relaxation of hydrogen
nuclei in surrounding water. We show that a Mn-doping of
B5% results in a transverse relaxivity, r2 = 16 mM
1 s1,
comparable to that of super-paramagnetic iron oxide particles.27
However, we note that the use of iron oxide particles for cell
transplantation tracking and intra-operative guidance is limited
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due to the hypointensity generated in MRI images being indistin-
guishable from small bleeds.26 Thus Mn-doped nanoparticles could
be advantageous. Here we demonstrate the eﬀect of our nanocrystals
on neuronal cell viability and show that at non-toxic concentrations
(o0.05 mg mL1) the QDs, uptaken by neuronal cells, alter
significantly the water relaxation properties thus providing
contrast in MRI. Since these nanoparticles are also fluorescent
with emission tuneable in the NIR,28,29 they have potential for
applications in dual in vivo imaging.
Colloidal Mn-doped PbS nanocrystals are synthesised in
aqueous solution with Mn-content up to 7%. A mixture of
1-thioglycerol and 2,3-dimercapto-1-propanol is used to stabilise
the nanocrystals and to make them water soluble. Triethylamine
(Et3N) is used to control the pH of the QD solution. Mn
2+ is
incorporated as substitutional impurity into the Pb-sublattice
thus forming alloyed (PbMn)S nanocrystals with room tempera-
ture photoluminescence (PL) emission tuneable by Mn-content
in the range 850–1200 nm.25 Transmission electron microscopy
(TEM) and high-resolution (HR) TEM images indicate that the
QDs have average diameter d = 4.5  1.2 nm, independent of Mn
content, and confirm that alloyed nanocrystals retain high
crystallinity (Fig. 1 and ESI,† Fig. S1).
NMR provides a powerful technique for determining the
eﬀect of paramagnetic impurities on proton spin relaxation
time constants (i.e. T1 and T2) as well as a method for structural
characterization. Here we use NMR spectroscopy to probe the
interaction between the paramagnetic Mn2+ ions encapsulated
into the QDs and the protons in surrounding molecules. In
particular, we focus on the relaxation properties of protons of
the –CH3 and –CH2 groups of Et3N molecules present in the
solvent. The NMR spectra of PbS and (PbMn)S QDs recorded at
T = 298 K (Fig. 1c) show two intense and resolved peaks. By
comparing these spectra to that of Et3N in water (not shown),
we assign the quartet at 3.12 ppm and the triplet at 1.24 ppm to
the –CH2 and –CH3 groups, respectively.
30 We attribute the
multiplet splitting to the spin–spin scalar coupling J = 7.7 Hz
for both –CH3 and –CH2, which is unchanged with respect to
those of the pure Et3N sample. However, for PbS QD solutions
we observe a significant down-field chemical shift of the
resonance peaks of Et3N by 0.71 ppm and 0.35 ppm for –CH3
and –CH2 groups, respectively. We note that the chemical shift
and J-couplings are independent of the proton concentration
(i.e.H2O/D2O ratio from 1 : 0.1 to 1 : 120) and pH of the solution.
Incorporation of Mn in the QDs leads also to an up-field shift of
0.06 ppm for CH2 and of 0.035 ppm for CH3 groups, and
broadening of the resonance lines. For a Mn-content larger
than 0.1%, the multiplet structures cannot be resolved. The
broadening suggests that the local magnetic moment of the
(PbMn)S QDs induces paramagnetic relaxation on the protons
of the Et3N molecules.
Analysis of the proton relaxation times in –CH2 and –CH3
groups of Et3N show a two orders of magnitude decrease from
T1 = 2.40  0.09 s for –CH2 and T1 = 2.66  0.04 s for –CH3
groups in the PbS QD solution to 0.024  0.003 s and 0.027 
0.002 s, respectively, for (PbMn)S with Mn = 3%. The length of
the capping molecules used to terminate the growth of the
nanocrystals is o0.5 nm and allows free diffusion of Et3N
molecules to the QD surface resulting in a significant decrease
of the relaxation times via paramagnetic relaxation effects.
Similar effects are observed for the relaxation properties of
water proton spins in MRI. As shown in Fig. 2a, our MRI studies
show that T1 and T2 relaxation times are significantly decreased
by an increasing Mn-content. For solutions with 7% Mn and
QD concentration of 5 mg mL1, we observe a decrease of T1
and T2 by one and two orders of magnitude, respectively,
compared to identical control samples with 0% Mn. This increase
of relaxation rates by B100-times is comparable to the change
estimated in our NMR studies. We note that in undoped PbS QD
solutions the relaxation rate of the water protons is not noticeably
affected by the presence of the nanocrystals. As shown in the inset
of Fig. 2a, the Mn-induced change of T1 and T2 provides significant
contrast in MRI images of QD solutions.
We envisage that Mn-ions in closer proximity to the QD
surface aﬀect predominantly the relaxation of the surrounding
water protons. By assuming a uniform distribution of Mn
throughout a spherical nanocrystal, we estimate that the number
of Mn-ions within a distance of 0.5 nm from the QD surface
increases from B25 for Mn = 1% to B150 for Mn = 7%. On the
other hand, the broadening of the NMR lines and the non-linear
decrease of T1 and T2 with increasing Mn-content indicate much
stronger eﬀects at low Mn content (Mno 1%), thus suggesting
the preferential location of Mn close to the periphery of the
nanocrystal.31 Self-purification mechanisms4 can lead to
impurity out-diﬀusion resulting in greater impurity content in
the proximity of the QD surface compared to the centre.32 The
greater Mn-dependent reduction of T1 and T2 times at low Mn
compared to higher Mn content indicates a saturation of the
concentration of Mn-ions close to the QD surface.
Fig. 1 (a) A typical high resolution TEM image of a Mn-doped PbS nanocrystal
and (b) a schematic representation of a Mn-doped quantum dot capped with a
layer of capping molecules (thioglycerol) in aqueous solution with trimethyla-
mine (dashed circle) used to control the pH. (c) NMR spectra of PbS and (PbMn)S
QDs revealing resonance lines characteristic for triethylamine (inset).
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Representative T1 and T2 times of serial dilution of (PbMn)S
QDs with 4.5% and corresponding T2-weighted images are
shown in Fig. 2b. To facilitate the comparison with other works,
we assess the relaxivity per Mn concentration: at room tem-
perature and magnetic field B = 7 T, we find r1 = 5 mM
1 s1
and r2 = 16 mM
1 s1, for T1 and T2, respectively. The para-
magnetism of the QDs, water accessibility and rotational
dynamics are likely causes for the more pronounced T2 eﬀect
compared to T1 in these QDs. To assess the eﬀect of environ-
ment viscosity, and thus water diﬀusion, on the QD-induced
changes of relaxivity, we performed the MRI studies of QDs
dispersed in 0.5% agarose and found no noticeable diﬀerences
in the values of T1 and T2 compared to those in water. This
suggests that similar eﬀects should be observed in cells and/or
tissues. Our investigations demonstrate relaxivity values that
are similar or greater than those reported for Mn-doped II–VI
QDs.19,20 Remarkably, the relaxivity values of r2 are similar to
those of Fe-based superparamagnetic nanoparticles (SPIONs)26
and only 10-times lower compared to commercial Fe-based
contrast agents.33 Since our Mn-doped QDs are significantly
smaller (d B 5 nm) compared to clinically approved Fe-based
particles (d4 100 nm),33 the greater cellular uptake combined
with the large relaxation rates could provide better contrast in
MRI. Also, following the incorporation of Mn, the QDs remain
optically active in the NIR wavelength range, as shown in Fig. 2c
for Mn = 1 and 4.5%.
Imaging of neural cells is of great importance for assessing
cell transplant therapies34 and Mn-based contrast agents have
been considered of great promise.11,35,36 One of the main
concerns in applications of the QDs is their penetration
through the blood–brain barrier, which could be controlled
by functionalization of the nanocrystals with cell penetration
peptides.37 To investigate the potential of our (PbMn)S QDs for
neuronal imaging, we have exposed the N2a mouse neuro-
blastoma cells to QDs with Mn content of 4.5% for 24 hours.
Our TEM images reveal localized QD clusters in the cytoplasm
indicating that the cellular uptake occurs via endocytosis.38,39
The cellular uptake is sufficient to allow photoluminescence/
absorption of the QDs to be detected in cells and cell pellets.
For MRI, the cell pellets of equal volume in Eppendorf tubes
were positioned at the centre of a 7 T magnet. T2-Weighted MRI
images of cell pellets (Fig. 3) reveal a QD-induced contrast for
QD treatment concentrations of 0.005mgmL1 and 0.01mgmL1.
The 3-fold change in MRI intensity for the cells exposed to (PbMn)S
QDs compared to the control sample is easily discernible by eye
and comparable to the contrast achieved with SPIONs23 and in
Mn-enhanced MRI.11,36
We note that the QD concentrations used in MRI are non-
toxic to the cell. We compare the cytotoxicity of (PbMn)S in two
representative cell lines: N2a and WGE. The N2a is an immortal
neural cell line derived from mouse neuroblastoma tumours
Fig. 2 (a) Eﬀect of Mn-content in the PbS nanocrystals on the MRI
relaxation times. Inset: T1 and T2 images for water and aqueous solutions
of PbS and (PbMn)S (Mn = 4.5%) QDs. (b) Eﬀect of representative QD
concentration on water relaxation times for QDs with Mn = 4.5%. Inset:
Corresponding T2-weighted images of QD solutions. (c) Room tempera-
ture normalized photoluminescence (PL) spectra of QDs with Mn content
of 1% and 4.5%.
Fig. 3 T2-Weighted image of neuronal cell pellets following 24 h expo-
sure to (PbMn)S QDs (Mn = 5%) and a corresponding histogram of the
detected MRI signal.
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that can be diﬀerentiated into neurones. The primary WGE
cells were dissected from developing mouse embryos at E14
and have the potential to become neurones or glial cells of the
adult striatum. For MTT analysis to test neuronal viability
in vitro, the N2a and WGE cells were treated with (PbMn)S
QDs for up to 72 h (Fig. 4a).
Additionally, primary cells were assessed over 7 days following
exposure to QDs. The highest dose which did not induce
significant cell death at any time point (24, 48 and 72 hours
and 7 days) in the primary cell cultures was determined to be
0.01 mg mL1, and there was a trend towards N2a cells being
less resilient to the eﬀects of the QDs. The growth inhibition
values for N2a and WGE cells (GI50
= 0.05 mg mL1) are lower
compared to fibroblast cells,35 indicating higher sensitivity of
neuronal cells to QD induced toxicity. Optical microscopy
assessment of N2a cells revealed reduced cell density and loss
of membrane integrity at QD treatment concentrations above
0.1 mg mL1, indicative of cell death (inset in Fig. 4a). Follow-
ing 7 day treatment with 0.01 mg mL1 (PbMn)S QDs (Fig. 4b)
GFAP immunocytochemistry analysis revealed no alterations to
the diﬀerentiation and morphology of cells. However, at treat-
ment concentration of 40.05 mg mL1, cell death occurred
and surviving GFAP neurones exhibited altered morphology.
There is no noticeable release of Mn-ions from the QD since the
QD induced toxicity levels are comparable to those of PbS QDs
and are independent of the Mn-content. Recent studies raised
concerns about possible ROS-induced cell damage (e.g. DNA
damage) following exposure to nanoparticles.40,41 We note that
at concentrations below GI50 values we do not observe any
QD-induced changes to cell viability and proliferation as
probed by MTT assay, cell cycle and annexin V studies, and
ROS.28,38 Our previous acute toxicity studies have demonstrated
that PbS-based QDs do not accumulate in the organs, are well
tolerated by mice, and their NIR photoluminescence can be
imaged in vivo.34
Conclusions
In conclusion, we have demonstrated that Mn-doped PbS QDs
can be used as biocompatible MRI probes. By encapsulating the
nanocrystals with a thin layer of capping molecules, we enable
the free diﬀusion of water molecules to the QD surface resulting
in a decrease of proton relaxation times and contrast in MRI. At
the concentrations where these QDs do not exhibit cellular
toxicity, the T2-weighted images reveal a 3-fold change of MRI
intensity. The combination of paramagnetism and fluorescence
emission in the near-infrared wavelength range of low absorp-
tion of biological tissues makes these QDs promising candidates
for dual medical imaging. Presently, specific targeting of these
QDs is being explored and combined in vivo mice imaging is
being developed in conjunction with extension of the detection
range of current fluorescence live animal imaging systems to
the NIR.
Experimental section
Morphological, optical and NMR studies
For the transmission electron microscopy (TEM) study, the
nanocrystals were deposited on a graphene-oxide coated grid
and TEM images were recorded on a JEOL1200EX microscope
operating at 120 kV.
Optical properties of quantum dots were measured in
solution and in agarose gel pellets. The optical excitation was
provided by the 532 nm line of a solid state laser and an
excitation power in the range P = 10–100 W m2. The lumines-
cence was dispersed by a 150 g mm1 grating and detected by
either a nitrogen-cooled (InGa)As array photodiode or a charge-
coupled device (CCD). We note that aqueous solutions of
PbS:Mn are stored at T = 4 1C under nitrogen atmosphere
and are stable over a period of at least 3 month. The colloidal
stability of aqueous nanoparticles can be altered by oxidation of
the surface and/or removal of the capping ligands and care
should be taken when subjecting QDs to high temperatures
(T4 50 1C) and/or low pH environment. The Nuclear Magnetic
Resonance (NMR) data were collected at 600 MHz on a Bruker
Avance III spectrometer at 298 K on QDs dispersed in H2O :D2O
(1 : 9). Solvent suppression was achieved using excitation
sculpting, where required. T1 experiments were conducted with
an inversion recovery sequence: p–delay (T)–p/2–free induction
decay. Data were acquired as a pseudo 2D and the relaxation
delay was set at45 T1 to facilitate complete recovery between
Fig. 4 (a) MTT analysis of cell viability after 48 hours of QD treatment
(Mn = 1%). All experiments were repeated 3-times with 6 replicates each;
error bars represent standard error of the mean. Inset: Optical images of
N2a cells following 48 h exposure to diﬀerent QD concentrations. (b) GFAP
immunocytochemistry of primary cells (WGE) untreated and following 7 days
exposure to QDs.
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transients. Data were phased and baseline corrected prior to
integration using TOPSPIN 3 software.
Magnetic resonance imaging (MRI)
All MRI experiments were performed on a horizontal Bruker
Biospec 7 T Avance III scanner (Bruker Biospin MRI GmbH,
Ettlingen, Germany) with a 7 cm transmit/receive volume coil.
QD solutions were extensively dialysed to remove the residual
free Mn-ions. 1 mL of samples in Eppendorf tubes were posi-
tioned in a polystyrene holder. Relaxometry measurements were
performed by taking a gradient echo localiser scan to establish
central positioning of the samples in the magnet, followed by a
Rapid Acquisition with Relaxation Enhancement Variable Time
of Repetition (RARE-VTR) fast spin echo T1/T2 scan. Scanner
software (Paravision 5.1) was used to determine a 0.15 cm2
region of interest for each sample and to obtain relaxation
values. A series of eight echo times (TE from 6.5 ms to 240 ms)
and inversion times (TI from 30 ms to 13 s) were optimised, and
T1 and T2 relaxation curves were plotted. The following para-
meters were used for all relaxation measurements: matrix size =
128  128, field of view (FOV) 80 mm/70 mm  50 mm, slice
thickness 1.5 mm and acquisition time taq B 11 min.
MTT and immunofluorescence assays
The cells were seeded into 96-well plates at a density of 6  103
per well and allowed 24 hours to adhere before treatment with
serially diluted QD solutions (from 5 mg mL1 to 0.5 mg mL1)
for up to 72 h. Control wells received the vehicle alone.
Following exposure, MTT was added to each well at a final
concentration of 5 mg mL1 and incubated at 37 1C for 30 min.
Supernatants were aspirated and cellular formazan solubilised
by the addition of DMSO and absorbance was read at 550 nm.
Primary striatal cells from mouse embryos (WGE) were seeded
at a density 5  104 per well and were exposed to QDs (0, 0.01,
0.05 and 0.1 mg mL1) for 7 days. Then the cells were fixed with
4% paraformaldehyde for 15 minutes, washed several times in
PBS, permeabilised for 10 minutes (PBS with 0.25% Triton
X-100) and blocked with 10% goat serum, 0.25% Triton X-100
and 0.3 M glycine in PBS for 1 hour. Primary antibodies were
diluted as follows: NeuN (to visualise neuronal cell nuclei,
monoclonal; 1 : 2000) and GFAP (to visualise glial cells, poly-
clonal; 1 : 1000) in 1% BSA, 0.3 M glycine, 0.25% Triton X-100 in
PBS and were incubated overnight at 4 1C. The cells were
washed extensively with PBS and then incubated in the dark
with the secondary antibody (1 : 500) in 1% BSA, 0.25% Triton
X-100 and 0.3 M glycine in PBS for 1 hour. After further three
PBS washes, the cells were counter stained with DAPI (1 : 1000),
washed in distilled water. The cover slip was applied using
DABCO mounting medium before being viewed under a Nikon
microscope.
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